Syn­thet­ic bi­ol­o­gy pi­o­neer Syn­thorx re­cruits Cleave's Lau­ra Shawver for top po­si­tion

Promi­nent biotech ex­ec­u­tive Lau­ra Shawver is tak­ing the helm at Syn­thorx, a lit­tle-known start­up blaz­ing the trail for syn­thet­ic bi­ol­o­gy — a field that promis­es to shake up drug de­vel­op­ment.

Lau­ra Shawver

In Shawver, Syn­thorx is get­ting an ex­pe­ri­enced leader who may be able to take the tiny biotech out of rel­a­tive ob­scu­ri­ty. Her ap­point­ment, which be­gins im­me­di­ate­ly, gives her the ti­tles of pres­i­dent, CEO and di­rec­tor. Shawver’s prob­a­bly best known for her role in snag­ging Cleave Bio­sciences a size­able in­fu­sion of cash with its re­cent $37 mil­lion Se­ries B. The com­pa­ny, found­ed in 2010, is de­vel­op­ing can­cer treat­ments via pro­tein degra­da­tion in­hibitors.

Syn­thorx will like­ly need some fresh cap­i­tal of its own. The com­pa­ny raised $10 mil­lion last Ju­ly to fund pre­clin­i­cal de­vel­op­ment in ar­ti­fi­cial pro­teins. Syn­thorx has lofty am­bi­tions of cre­at­ing en­tire­ly new ther­a­peu­tic pro­teins and pep­tides by tin­ker­ing with the col­lec­tion of amino acids used by na­ture to build them. The com­pa­ny’s tech is based on land­mark re­search by Scripps’ Floyd Romes­berg, which Syn­thorx hopes to use to make im­proved pro­tein ther­a­peu­tic can­di­dates (which the com­pa­ny calls “Syn­thorins”).

“We are all stoked to now move to the next phase demon­strat­ing that Syn­thorins can help pa­tients in a way not pre­vi­ous­ly pos­si­ble,” Shawver said in a state­ment. “It is tru­ly rev­o­lu­tion­ary tech­nol­o­gy that we in­tend to trans­form in­to break­through drugs, and I am look­ing for­ward to work­ing with the Syn­thorx team to do just that.”

Be­fore Cleave, Shawver was an en­tre­pre­neur-in-res­i­dence for 5AM Ven­tures, CEO and di­rec­tor of Phe­nomix Cor­po­ra­tion, and pres­i­dent of Sug­en (ac­quired by Phar­ma­cia). Shawver has been in­volved with a num­ber of clin­i­cal de­vel­op­ment pro­grams in­clud­ing two FDA-ap­proved ther­a­pies.

Jay Lichter

Syn­thorx has stayed most­ly qui­et since los­ing its last chief ex­ec­u­tive ear­li­er this year. Court Turn­er, a well-known ven­ture cap­i­tal­ist at Aval­on Ven­tures, held the CEO job from the com­pa­ny’s 2014 in­cep­tion un­til his de­par­ture in Au­gust.

Syn­thorx is a port­fo­lio com­pa­ny of Aval­on, where Turn­er was a long­time part­ner. Aval­on’s in­cu­ba­tor-like ven­ture stu­dio, COI Phar­ma­ceu­ti­cals, funds and man­ages sev­er­al biotech star­tups un­der its wing. But when he left Aval­on, Turn­er ab­di­cat­ed lead­er­ship po­si­tions at the com­pa­ny’s port­fo­lio firms as well.

Aval­on’s man­ag­ing part­ner Jay Lichter said the com­pa­ny was on the hunt for Turn­er’s re­place­ment back in Au­gust.

Shawver’s ap­point­ment is some­what un­usu­al for an Aval­on-backed start­up. Lichter’s hall­mark is to cre­ate small com­pa­nies based on promis­ing re­search, back them with Aval­on mon­ey, house them in COI, and lead the star­tups him­self. Some­times an­oth­er Aval­on part­ner will sit as CEO, split­ting time be­tween mul­ti­ple com­pa­nies.

But Lichter said Syn­thorx had out­grown the VC nurs­ery, and need­ed a full-time CEO to take the helm.

“You can’t do an IPO or a big ven­ture raise with a part-time CEO boot­strapped across three or four com­pa­nies,” Lichter tells me. “The tech has had a ma­jor in­flec­tion, and as a re­sult we need full-time A-team tal­ent to run the com­pa­ny.”

I asked Lichter how tiny Syn­thorx at­tract­ed “A-team” tal­ent. Af­ter all, Cleave was well-cap­i­tal­ized and ad­vanc­ing an ex­cit­ing pipeline.

“She fell in love with the tech­nol­o­gy,” Lichter said.

 

Am­ber Tong con­tributed to this re­port.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its board. “Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market,” said Seer chief and founder Omid Farokhzad in a statement.

Daniel O'Day

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunting up a CSO for the company isn’t stopping the industry’s dominant antiviral player from doing pipeline deals.

The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses. We don’t know what the upfront is, but the back end has $291 million in milestones baked in.

Vas Narasimhan, AP Images

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

Novartis CEO Vas Narasimhan is living in the sweet spot right now.

The numbers are running a bit better than expected, the pipeline — which he assembled as development chief — is performing and the stock popped more than 4% on Thursday as the executive team ran through their assessment of Q2 performance.

Year-to-date the stock is up 28%, so the investors will be beaming. Anyone looking for chinks in their armor — and there are plenty giving it a shot — right now focus on payer acceptance of their $2.1 million gene therapy Zolgensma, where it’s early days. And CAR-T continues to underperform, but Novartis doesn’t appear to be suffering from it.

So what could go wrong?

Actually, not much. But Tim Anderson at Wolfe pressed Narasimhan and his development chief John Tsai to pick which of two looming Phase III readouts with blockbuster implication had the better odds of success.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.